Salman Abbasey, MD
Internal Medicine · Geneseo, NYNPI 1053419028
Payments from drug & device makers
Across 336 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$547
- GSK$509
- Lilly USA, LLC$488
- Pfizer$422
- Novartis$303
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,00798%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,060 |
| AstraZeneca | 32 | $547 |
| GSK | 40 | $509 |
| Lilly USA, LLC | 37 | $488 |
| Pfizer | 23 | $422 |
| Novartis | 17 | $303 |
| Johnson & Johnson | 14 | $222 |
| Boehringer Ingelheim | 12 | $211 |
| Gilead | 6 | $159 |
| Astellas Pharma US Inc | 5 | $138 |
| Merck | 8 | $126 |
| Bayer | 7 | $122 |
| Amarin Pharma, Inc. | 9 | $122 |
| Paratek Pharmaceuticals, Inc. | 5 | $76 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Biohaven Pharmaceuticals, Inc. | 5 | $74 |
| Amgen | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| Eisai Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Corcept Therapeutics | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Abbott | 2 | $25 |
| Inogen, Inc. | 1 | $18 |
| SK Life Science, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$5,103 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 355 | $130,304 |
| OzempicSemaglutide | 83 | $93,448 |
| JardianceEmpagliflozin | 53 | $55,390 |
| JanuviaSitagliptin Phosphate | 63 | $46,962 |
| RybelsusSemaglutide | 22 | $43,608 |
| TrulicityDulaglutide | 24 | $31,646 |
| MounjaroTirzepatide | 27 | $30,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $30,287 |
| FarxigaDapagliflozin Propanediol | 29 | $27,287 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $22,464 |
| XareltoRivaroxaban | 34 | $21,585 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $21,144 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $18,932 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $15,632 |
| LinzessLinaclotide | 26 | $15,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,060 | $137,056105 claims |
| PfizerEliquis | $422 | $130,304355 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $509 | $85,994140 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $488 | $62,25551 claims |
| Boehringer IngelheimJardiance | $211 | $55,39053 claims |
| MerckJanuvia | $126 | $46,96263 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $547 | $33,32655 claims |
| Johnson & JohnsonXarelto | $222 | $21,58534 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $13,88530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Geneseo
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.